Boston Aesthetics Taps InMode Veteran Brandon Nye to Drive Growth in Crowded Market

IRVINE, CA – April 13, 2026 – In a strategic move signaling aggressive growth ambitions, Boston Aesthetics today announced the appointment of medtech industry veteran Brandon Nye as its new Chief Executive Officer. Nye, who joins the company from competitor InMode, is tasked with steering the firm's commercial expansion and strategic initiatives as it navigates the complex and rapidly evolving global medical aesthetics sector.

The appointment, effective immediately, places a proven sales leader at the helm of a company aiming to carve out a significant market share. Boston Aesthetics, powered by the extensive manufacturing and R&D capabilities of its parent company, Peninsula Medical Group, is positioning itself to challenge established players by focusing on what it calls “Beauty With No Boundaries”—a philosophy centered on combining strong clinical results with a superior treatment experience and sustainable practice economics for providers.

A Growth Architect Takes the Helm

Brandon Nye is no stranger to hyper-growth environments. A 15-year industry veteran, he most recently served as Vice President of Sales at InMode, a prominent player in the energy-based medical device market. During his tenure, Nye was instrumental in driving significant commercial success, reportedly contributing to over $500 million in career sales and earning the title of Sales Director of the Year for three consecutive years from 2019 to 2021. His track record is built on building high-performing sales teams and scaling commercial operations for capital equipment—a skillset directly aligned with Boston Aesthetics' immediate goals.

His appointment is a clear signal of the company's intent to aggressively pursue market penetration. Nye’s vision extends beyond simply selling devices. "As the aesthetics market evolves, providers increasingly need solutions that combine strong clinical outcomes with sustainable economics and a better treatment experience," said Nye in a statement. "Our focus is to build differentiated technologies and commercial models that support long-term utilization, strong customer partnerships, and durable value creation."

This approach directly addresses a key pain point for practitioners in a market characterized by high equipment costs and what the company terms “tighter capital conditions.” By emphasizing flexible go-to-market pathways and long-term partnerships, Nye aims to lower the barrier to entry and ensure that technology adoption translates into sustained profitability for clinics.

Navigating a Dynamic and Demanding Market

Nye steps in at a pivotal moment for the medical aesthetics industry. The market, valued at over $82 billion in 2023, is projected to grow at a robust CAGR of over 8% through 2030. This growth is fueled by expanding patient demographics, including younger generations and men who view aesthetic treatments as part of a routine self-care regimen. However, the landscape is also becoming more complex.

Patient demand is shifting towards non-invasive and minimally invasive procedures that offer natural-looking results with minimal downtime. Furthermore, the recent surge in medical weight-loss therapies, such as GLP-1 medications, has introduced a new dynamic, creating both opportunities and new clinical considerations for aesthetic providers. Boston Aesthetics enters a fiercely competitive arena dominated by established giants like the newly merged Cynosure Lutronic, Lumenis, and Candela. Nye’s challenge will be to differentiate the company’s offerings in this crowded field.

"At Boston Aesthetics, we believe the future of aesthetics must be built on more than clinical outcomes alone," stated Shawn Ho, Chief of Staff for Peninsula Medical Group and Head of Business Development for Boston Aesthetics. "It must also create lasting value for providers, reduce friction in adoption and use, and deliver a better experience for patients. We do not believe meaningful aesthetic results should come at the cost of pain, inefficiency, or unnecessary burden."

The Global Powerhouse Advantage

The key to Boston Aesthetics’ strategy may lie in its powerful parent company. Headquartered in the global tech hub of Shenzhen, China, Peninsula Medical Group provides a formidable backbone of engineering and manufacturing prowess. The group boasts a research and development team of more than 400 engineers dedicated to rapid innovation in energy-based technologies.

This relationship provides Boston Aesthetics with a unique competitive advantage: the ability to combine the agility and market focus of its Irvine, California headquarters with the scale and innovation engine of a global manufacturing leader. The company’s product portfolio, which includes a Fractional RF Platform, Microfocused Ultrasound (MFUS), and RF Microneedling systems, is a direct result of this synergy. These technologies are designed to meet the market's demand for effective, 'comfort-first' treatments.

"Peninsula Medical Group's strategy has always been grounded in clinical outcomes, scalable innovation, and long-term partnership models," Ho added. "Our investment in Boston Aesthetics reflects a strong belief that success in the U.S. market requires both local commercial agility and deep global capabilities in engineering, manufacturing, and innovation."

Under Nye’s leadership, the company is expected to leverage this global-local model to its fullest potential. The strategy is to accelerate the development of next-generation devices while building a commercial infrastructure in the U.S. that is deeply attuned to the needs of physicians and practitioners. As the industry continues its trajectory of rapid growth and transformation, Boston Aesthetics is betting that its blend of innovative technology, provider-centric business models, and seasoned leadership will be the formula for success. The company will continue to operate from its headquarters in Irvine, leveraging these global capabilities to accelerate its push into the American market.